Galenica AG (GALE.SW) stock analysis

In our weekly check, Galenica AG is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2.

About Galenica AG

Galenica AG is a Healthcare company (Medical - Distribution) based in Switzerland, listed on SIX as GALE.SW.

What our checks show for GALE.SW

Red flags

• The net margin is only 4.4%: little room if costs rise.
• Thinly traded (about 91 thousand shares a day): buying and selling can move the price.

Warning signs

• Analysts expect only about 4.4% a year of growth in revenue.
• Revenue grew only 1% a year over the last 3 years.
• Return on capital (ROCE) is only 9%.

Strengths

• Operating profit covers interest 17.3 times over.
• The gross margin is 10.4% and has risen by 1.2 points: pricing power is holding.
• Operating cash flow is 1.66x net profit: the profit arrives as real cash.
• The price moves calmly: 15.6% annual volatility.
• Beta 0.26: the stock usually moves less than the market.
• Pay in shares is only 2.7% of free cash flow.

Similar companies

HSIC · SIG.AX

Questions

What grade does Galenica AG (GALE.SW) have?

In our weekly check, Galenica AG is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of GALE.SW stock?

This week's biggest flags for Galenica AG: Thin margins, Thinly traded, Weak revenue forecast. In total 5 of 25 checks show a warning or a red flag.

What does Galenica AG do?

Galenica AG is a Healthcare company (Medical - Distribution) based in Switzerland, listed on SIX as GALE.SW.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis